ipriflavone has been researched along with Fibroid in 3 studies
ipriflavone : A member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ipriflavone efficaciously alleviated the adverse effects of estrogen deficiency such as bone loss and increase in LDL-C level, and the ability of leuprolide therapy to reduce myoma volume was not decreased by ipriflavone administration." | 2.70 | Efficacy of ipriflavone in preventing adverse effects of leuprolide. ( Aso, T; Chiguchi, M; Ishibashi, T; Somekawa, Y; Wakana, K, 2001) |
| "Uterine fibroids (also known as leiomyomas) are the most common benign pelvic tumours among women." | 2.52 | Add-back therapy with GnRH analogues for uterine fibroids. ( Brito, LG; Candido Dos Reis, FJ; Ferriani, RA; Martins, WP; Moroni, RM; Nastri, CO; Vieira, CS, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moroni, RM | 1 |
| Martins, WP | 1 |
| Ferriani, RA | 1 |
| Vieira, CS | 1 |
| Nastri, CO | 1 |
| Candido Dos Reis, FJ | 1 |
| Brito, LG | 1 |
| Gambacciani, M | 1 |
| Cappagli, B | 1 |
| Piaggesi, L | 1 |
| Ciaponi, M | 1 |
| Genazzani, AR | 1 |
| Somekawa, Y | 1 |
| Chiguchi, M | 1 |
| Ishibashi, T | 1 |
| Wakana, K | 1 |
| Aso, T | 1 |
1 review available for ipriflavone and Fibroid
| Article | Year |
|---|---|
Add-back therapy with GnRH analogues for uterine fibroids.
Topics: Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combi | 2015 |
2 trials available for ipriflavone and Fibroid
| Article | Year |
|---|---|
Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists.
Topics: Absorptiometry, Photon; Analysis of Variance; Antineoplastic Agents, Hormonal; Bone Density; Bone Re | 1997 |
Efficacy of ipriflavone in preventing adverse effects of leuprolide.
Topics: Adult; Bone Density; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Estrogen Antagonists; Female; | 2001 |